ALK and non-small cell lung carcinoma: The concomitant use of systemic tyrosine kinase inhibitors (TKIs) and local treatments prolong patients’ survival, as observed in a retrospective analysis, including 90 ALK positive NSCLC patients who reached a median overall survival (OS) of more than four years [5].